HMGA2 enhances 5-fluorouracil chemoresistance in colorectal cancer via the Dvl2/Wnt pathway

Xi Xu; Yunfeng Wang; Hong Deng; Chungang Liu; Jingjing Wu; Maode Lai

doi:10.18632/oncotarget.24133

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

HMGA2 enhances 5-fluorouracil chemoresistance in colorectal cancer via the Dvl2/Wnt pathway

Xi Xu _, Yunfeng Wang, Hong Deng, Chungang Liu, Jingjing Wu and Maode Lai

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2018; 9:9963-9974. https://doi.org/10.18632/oncotarget.24133

Metrics: PDF 1763 views | HTML 2718 views | ?

Abstract

Xi Xu1,2, Yunfeng Wang3, Hong Deng1,2, Chungang Liu1,2,4, Jingjing Wu1,2 and Maode Lai1,2

1Department of Pathology, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310058, China

2Key Laboratory of Disease Proteomics of Zhejiang Province, Hangzhou, Zhejiang, 310058, China

3College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, Heilongjiang, 150081, China

4Center of Biological Therapy, Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University, Chongqing, 400038, China

Correspondence to:

Maode Lai, email: [email protected]

Jingjing Wu, email: [email protected]

Keywords: HMGA2; Dvl2; 5-FU; chemoresistance; colorectal cancer

Received: July 12, 2017 Accepted: December 03, 2017 Published: January 10, 2018

ABSTRACT

Drug resistance is one of the main hurdles to overcome for the improvement of cancer patient survival. However, the underlying mechanisms remain largely unknown, and therapeutic options are limited. Here, we demonstrate a strong correlation between HMGA2 expression and chemosensitivity to 5-fluorouracil (5-FU), a widely used first-line systemic chemotherapy regimen for colorectal cancer (CRC) patients. Overexpression of HMGA2 enhances chemoresistance to 5-FU of CRC both in vitro and in vivo. Further experiments indicate that HMGA2 directly binds to the promoter of Dvl2 and induces its transcription, which leads to increased activation of the Wnt/β-catenin pathway. Taken together, our data suggest that HMGA2 enhances the chemoresistance to 5-FU in CRC via activating the Dvl2/Wnt pathway. Therefore, HMGA2 may serve as a predictive biomarker and a potential therapeutic target in CRC.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 24133

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

HMGA2 enhances 5-fluorouracil chemoresistance in colorectal cancer via the Dvl2/Wnt pathway

Abstract